In FLT3-mutant AML, treatment with FLT3 inhibitors like quizartinib mediates the augmentation of inflammatory pathways in DTP cells, characterized by the activation of transcription factors and cytokines involved in inflammation (33). This evidence concerns the gene FLT3 and acute myeloid leukemia.